Skip to main content

DBV Jumps 41% To $9.96 After Update On Viaskin Peanut Filing

Shares of DBV Technologies jumped after the company said that its planned resubmission of the Biologics License Application to the FDA for Viaskin Peanut is anticipated in the third quarter of 2019.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.